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Key Messages
 Relapse of transient neonatal diabetes mellitus (TNDM), when it occurs in adulthood, presents a diagnostic challenge; affected
individuals are often misclassiﬁed resulting in suboptimal treatment.
 Our report highlights the importance of TNDM in the medical history as a crucial etiological clue to the adult diabetologist.
 This allows diagnosis of monogenic diabetes, leading to appropriate treatment and genetic counselling.a r t i c l e i n f o
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Neonatal diabetes mellitus is a rare form of monogenic diabetes
diagnosed before 6 months of age which occurs in approximately 1
in 100,000 live births (1). Nearly one-half of neonatal diabetes is
transient, with remissionwithin 1 to 18months followed by relapse
later in childhood or in adult life (2,3). Almost 90% of cases of
transient neonatal diabetes mellitus (TNDM) are caused by muta-
tions in the ATP-sensitive potassium (KATP) channel genes KCNJ11
and ABCC8 (4) or chromosome 6q24 imprinting abnormalities (5).
Activating mutations in KATP channels, formed by Kir6.2 (KCNJ11
gene) and SUR1 (ABCC8 gene) cause monogenic diabetes by
impairing the ability of pancreatic KATP channels to close inBS, PhD University of Exeter Medic
er Inc. on behalf of Canadian Dia
wner of the name Diabetes Canadresponse to metabolically generated ATP or falling Mg-ADP; this
leads to hyperpolarized beta cells, which are unable to secrete
insulin as blood glucose rises (6,7). Sulfonylureas can bind and close
pancreatic KATP channels independently of ATP, allowing insulin
secretion in both ABCC8 and KCNJ11 monogenic diabetes (7,8). The
mechanism by which 6q24 causes TNDM in humans remains
unknown; however, small scale human studies suggest ﬁrst phase
insulin secretion may be impaired, supporting treatment with
insulin secretagogues (9). A genetic diagnosis is, therefore, crucial
in TNDM because affected individuals may be successfully treated
with sulfonylureas instead of subcutaneous insulin (10,11).
Individuals with TNDM remain euglycemic after remission and
present later with relapse of diabetes often to an adult diabetologistal School, RILD Building, Level 3 - Medical Research, Royal Devon & Exeter Hospital,
betes Association. This is an open access article under the CC BY license (http://
a.
Table 1












FBG, mmol/L 5.8 7.7 5.4e7.8 8.2
PP-BG, mmol/L NK up to 9.0 up to 9.0 6.5e8.9
A1C, % NK 6.1 6.5 7.2
A1C, glycated hemoglobin; FBG, fasting blood glucose; NK, not known; PP-BG,
post-prandial blood glucose.
Table 2
Clinical features of 2 cases at presentation to the adult diabetes clinic
Clinical features at presentation Case 1 Case 2
Birth weight, g 2,950 1,600
Birth weight SD score 1.94 3.39
Family history of diabetes Yes, paternal grandmother
diagnosed at 45 years of age;
tablet treated
No
Clinical examination Normal Normal
Acanthosis nigricans No No
BMI, kg/m2 19.4 22.2
A1C, % 6.1 8.6
A1C, mmol/mol 43 70
GAD antibodies (þ/e) e e
IA-2A antibodies (þ/e) e e
UCPCR, nmol/mmol NK 2.72
C-peptide, nmol/L 0.58 NK
þ, positive; e, negative; A1C, glycated hemoglobin; BMI, body mass index; GAD,
glutamic acid decarboxylase; NK, not known; UCPCR, urine C-peptide creatinine
ratio.
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neonatal history may not be routinely taken. Here, we present 2
cases with TNDM, due to an ABCC8 mutation and 6q24 imprinting
abnormality, who presented as adults when their diabetes relapsed.
These cases highlight the importance of TNDM as a crucial etiologic
clue that can lead to a monogenic diagnosis and appropriate
treatment. Informed consent was obtained from both individuals
for the use of their clinical data in this report. Genetic analysis was
performed at the Royal Devon and Exeter Molecular Genetics
Laboratory in Exeter, United Kingdom.
Case 1
An asymptomatic 21-year-old Caucasianwomanwith no history
of diabetes was referred by her obstetrician to an adult diabetol-
ogist following the birth of her ﬁrst baby who was macrosomic
(birth weight, 5,140 g; birth weight SD score, 3.24); the baby did not
have postnatal hypoglycemia. Blood glucose and glycated hemo-
globin (A1C) values at different time points are summarized in
Table 1.
Clinical features at presentation to the diabetes clinic are sum-
marized in Table 2. Initial management comprised dietary changes
and regular review. She became pregnant 2 years later and was
managed with diet. She gave birth to a healthy baby girl, weighing
3,350 g (body weight SD score, 0.22). On day 6 of life, the baby
presented with mild, intermittent hyperglycemia (highest glucose
value, 13.1 mmol/L) that did not require glucose-lowering treat-
ment. Genetic analysis revealed that case 1 and her second baby are
heterozygous for the ABCC8 missense mutation, p.Arg1183Trp,
previously shown to cause TNDM (12). Postdelivery, case 1 was
started on gliclazide 15 mg daily (10% of the standard type 2 dia-
betes dose) (13) because of rising A1C. Blood glucose monitoring
showed fasting hyperglycemia. Her A1C improved from 7.2%
(55 mmol/mol) after delivery to 5.9% (41 mmol/mol) at most recent
follow up, 6 months after starting gliclazide. She has not reported
hypoglycemia, weight gain or other side effects on gliclazide.
Capillary glucose testing was not done because she was on oral
therapy. The child’s diabetes remains in remission needing no
treatment, and she is developmentally normal at 4 years of age.
Case 2
A 39-year-old Caucasian woman was referred to a diabetologist
with a 3-month history of polyuria, polydipsia, 3 kg weight loss and
cystitis. She had developed diabetes soon after birth requiring
twice daily insulin for 12 weeks. Her diabetes subsequently
remitted, and she had not required treatment until this presenta-
tion. Clinical features are summarized in Table 2. Because there was
a history of TNDM, genetic analysis was performed, revealing a
chromosome 6q24 imprinting abnormality. She started glyburide
2.5 mg/d (25% of the standard type 2 diabetes dose), and her A1C
improved to 6.5% (48 mmol/L) after 4months and 6.7% (50mmol/L)
after 13 months of treatment, with no side effects reported. Her
weight increased from 60.5 to 63.8 kg in the ﬁrst 4 months of
treatment, but she lost weight subsequently (63.1 kg after
18 months), and her body mass index remained <25 kg/m2
thereafter. Because she was planning a pregnancy when her dia-
betes relapsed, shewas also reassured that the risk of the same type
of diabetes in her children would be no higher than that in the
general population.
Discussion
These cases illustrate how a comprehensive history can be
fundamental in making a diagnosis of monogenic diabetes in adults,
which is crucial for correct clinical management. The mechanism ofremission and relapse in TNDM is not known, but many affected
individuals can be successfully treated at either stage with oral
glucose-lowering drugs, such as sulfonylureas instead of subcutane-
ous insulin (8,10,11), resulting inexcellentclinical outcomes (10,14,15).
Raﬁq et al (11) described successful transfer of 8 of 8 patients
with ABCC8 TNDM from insulin to sulfonylureas, resulting in
improvedmetabolic control in the subsequent 3months. Regarding
long-term efﬁcacy, there is strong evidence of good durability of
sulfonylureas over 10 years in KCNJ11 PNDM (16); such evidence is
not present for ABCC8 neonatal diabetes. However, the similar
molecular mechanism and short-term sulfonylurea effectiveness in
both subtypes of KATP channel neonatal diabetesmakes it likely that
sulfonylurea durability will also be similar.
Although sulfonylureas are the most common treatment for
individuals with 6q24 TNDM, there is currently no trial evidence of
superiority of these drugs over the other antidiabetic drugs, and
long-term sulfonylurea durability remains unknown. In a recent
review of 6q24-related TNDM, Garcin et al (10) described successful
sulfonylurea treatment in 11 patients (4 before remission and 7 in
the relapse phase); however, 4 of 7 patients in the relapse phase
also required additional oral therapies, such as metformin and
sitagliptin, to maintain metabolic control. This supports the effec-
tiveness of sulfonylureas in 6q24 TNDM to an extent, but further
long-term studies in larger cohorts are needed to conﬁrm their
durability. Despite this, a genetic diagnosis is still crucial because it
can mean avoidance of unnecessary insulin therapy.
In addition to its impact on treatment, identifying a speciﬁc
genetic etiology also allows accurate calculation of diabetes risk in
future offspring and counselling in relation to this. Offspring of
people with KATP channel mutations that cause TNDM are at 50%
risk of inheriting the mutation and developing neonatal diabetes
and/or adult-onset diabetes. In contrast, this risk with 6q24 TNDM
is dependent upon the speciﬁc genetic or epigenetic change (17).
Finally, KATP channel mutations have important implications for
clinical management during pregnancy, particularly regarding
glyburide therapy (18). Treatment recommendations in mothers
A. Novak et al. / Can J Diabetes xxx (2019) 1e3 3with KATP channel mutations are dependent on the fetal genotype
because of differing effects of treatment on fetuses with or without
the mutation (18). In the future, more widespread use of cell free
fetal DNA analysis in pregnancy (19) will allow noninvasive deter-
mination of fetal genotype to assist these treatment decisions.
Despite the importance of diagnosing monogenic diabetes,
many patients remain misdiagnosed (20) for several reasons.
Firstly, some of the clinical features associated with TNDM are also
seen in common polygenic subtypes of diabetes (type 1 and type 2
diabetes), limiting the utility of existing diagnostic tools in the
identiﬁcation of rare monogenic cases. C-peptide and autoantibody
testing can assist to an extent, but approximately 8% of those with
type 1 diabetes are C-peptide positive (21), and approximately 18%
are autoantibody negative (22), making such individuals indistin-
guishable from those with TNDM mutations based on these bio-
markers alone. The Maturity-Onset Diabetes of the Young (MODY)
probability calculator may be useful, but it is not validated for
patients with TNDM (23). Furthermore, penetrance of some
TNDM mutations is variable and not all affected will have a history
of neonatal diabetes (24,25). Low birth weight may point towards
the presence of monogenic diabetes under such circumstances
(25); however, this feature is not speciﬁc to TNDM.
Despite these caveats, the presence of neonatal diabetes is one
of the strongest clues for an underlying monogenic etiology
because >82% of individuals with neonatal diabetes have a
monogenic cause (4). International guidelines recommend genetic
testing for all patients with neonatal diabetes irrespective of clinical
features (26). Adoption of these guidelines is improving, particu-
larly in pediatrics, and with better case ascertainment and appro-
priate genetic counselling, misdiagnosis should become less
frequent in the future. However, large numbers of cases currently
remain unascertained, and it is therefore crucial to remain vigilant
for clues pointing towards a monogenic etiology in adults.
Conclusions
Adult diabetologists should routinely ask patients about a per-
sonal or family history of neonatal diabetes and low birth weight.
The presence of diabetes under 6 months of age makes a mono-
genic etiology very likely, and should prompt clinicians to under-
take genetic testing. In many cases, a genetic diagnosis will result in
optimization of treatment, accurate genetic counselling and
improved management of pregnancy.
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